Delayed recurrences and survival after relapse in patients initially treated with intraperitoneal chemotherapy for advanced ovarian cancer: A Gynecologic Oncology Group study.

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Survival After Relapse

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.12.057 ◽

2012 ◽

Vol 125 ◽

pp. S24-S25 ◽

Cited By ~ 3

Author(s):

L. Landrum ◽

J. Java ◽

C. Mathews ◽

G. Lanneau ◽

L. Copeland ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Epithelial Ovarian Cancer ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Long-term survival advantage of intraperitoneal chemotherapy treatment in advanced ovarian cancer: An analysis of a Gynecologic Oncology Group ancillary data study

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.04.065 ◽

2013 ◽

Vol 130 (1) ◽

pp. e4 ◽

Cited By ~ 5

Author(s):

D. Tewari ◽

J. Java ◽

R. Salani ◽

D. Armstrong ◽

M. Markman ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Oncology Group ◽

Chemotherapy Treatment ◽

Ancillary Data ◽

Term Survival

Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study

Annals of Oncology ◽

10.1093/annonc/mdv500 ◽

2016 ◽

Vol 27 (1) ◽

pp. 114-121 ◽

Cited By ~ 45

Author(s):

K.S. Tewari ◽

J.J. Java ◽

R.N. Eskander ◽

B.J. Monk ◽

R.A. Burger

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Complete Resection ◽

Early Initiation ◽

Oncology Group ◽

Phase III Gynecologic Oncology Group Study of Advanced Ovarian Cancer: Bevacizumab Added to Initial Chemotherapy Extends Progression-Free Survival

Oncology Times ◽

10.1097/01.cot.0000387947.51553.29 ◽

2010 ◽

Vol 32 (Sup 1) ◽

pp. 17

Author(s):

&NA;

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Progression Free Survival ◽

Phase Iii ◽

Oncology Group ◽

Free Survival ◽

A Phase II Study of Fazarabine in Patients with Advanced Ovarian Cancer A Gynecologic Oncology Group Study

American Journal of Clinical Oncology ◽

10.1097/00000421-199504000-00012 ◽

1995 ◽

Vol 18 (2) ◽

pp. 156-157 ◽

Cited By ~ 10

Author(s):

Alberto Manetta ◽

John A. Blessing ◽

Katherine Y. Look

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Oncology Group ◽

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.10.003 ◽

2016 ◽

Vol 143 (3) ◽

pp. 484-489 ◽

Cited By ~ 4

Author(s):

Arlene E Garcia-Soto ◽

James J Java ◽

Wilberto Nieves Neira ◽

J Matthew Pearson ◽

David E. Cohn ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Time Interval ◽

Prognostic Impact ◽

Oncology Group ◽

Oncology Group Study ◽

Ancillary Study ◽

Chemotherapy Administration

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.04.001 ◽

2013 ◽

Vol 130 (1) ◽

pp. 12-18 ◽

Cited By ~ 85

Author(s):

Lisa M. Landrum ◽

James Java ◽

Cara A. Mathews ◽

Grainger S. Lanneau ◽

Larry J. Copeland ◽

...

Keyword(s):

Ovarian Cancer ◽

Prognostic Factors ◽

Epithelial Ovarian Cancer ◽

Gynecologic Oncology ◽

Stage Iii ◽

Oncology Group ◽

Pilot Evaluation of High-Dose Carboplatin and Paclitaxel Followed by High-Dose Melphalan Supported by Peripheral Blood Stem Cells in Previously Untreated Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1006/gyno.2003.6882 ◽

2003 ◽

Vol 88 (1) ◽

pp. 3-8 ◽

Cited By ~ 26

Author(s):

Russell J. Schilder ◽

Mark F. Brady ◽

David Spriggs ◽

Thomas Shea

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

High Dose ◽

Oncology Group ◽

Peripheral Blood Stem Cells ◽

Oncology Group Study ◽

Blood Stem Cells ◽

High Dose Melphalan

Phase III randomized trial of maintenance pegylated liposomal doxorubicin (PLD) / carboplatin versus without in patients with advanced ovarian cancer: An Asian Gynecologic Oncology Group study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5584 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5584-5584

Author(s):

Chyong-Huey Lai ◽

Elizabeth Vallikad ◽

Hao Lin ◽

Lan-Yan Yang ◽

Yu-Che Ou ◽

...

Keyword(s):

Ovarian Cancer ◽

Randomized Trial ◽

Liposomal Doxorubicin ◽

Gynecologic Oncology ◽

Advanced Ovarian Cancer ◽

Pegylated Liposomal Doxorubicin ◽

Phase Iii ◽

Oncology Group ◽

Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2017.04.008 ◽

2017 ◽

Vol 146 (1) ◽

pp. 137-145 ◽

Cited By ~ 1

Author(s):

Shannon Grabosch ◽

George Tseng ◽

Robert P. Edwards ◽

Heather A. Lankes ◽

Kathleen Moore ◽

...

Keyword(s):

Ovarian Cancer ◽

Gynecologic Oncology ◽

Oncology Group ◽